Peripheral Neuropathy stem cell therapy — your questions answered (2026)

About stem cell therapy for Peripheral Neuropathy

Peripheral neuropathy is a broad category of nerve disorders caused by diabetes, immune disease, toxins, medicines, vitamin deficiency, infection, inherited conditions, compression and other processes. MSC, neural-cell and exosome proposals invoke neuroprotection or repair, but one mechanism cannot address every cause and laboratory neurite growth does not establish restored sensation or function.

The evidence for Peripheral Neuropathy

The diagnosis should define nerve type, distribution, cause and severity before any experimental product is considered. Studies must match the exact neuropathy, product, route, comparator and validated pain, sensory, motor and functional outcomes. FDA patient information states that regenerative medicine products marketed for neurological conditions require product-level review and warns of serious harms from unapproved products. Do not transfer evidence from spinal cord injury, diabetic ulcers or another neuropathy.

Itemise neurological assessment, cause-specific testing, exact product, administration, rehabilitation, travel, follow-up and management of infection or neurological deterioration. Preserve treatment of diabetes, deficiency, immune disease, compression or other identified causes and do not budget from a generic nerve-repair claim.

Can stem cells reverse neuropathy?

Cell therapy for Peripheral Neuropathy may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.

Diabetic vs idiopathic — which responds?

Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.

How many sessions?

Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.

EU cost?

The partner-published indicative range for an Peripheral Neuropathy programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.

Sources & further reading

We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.

• Open clinical trials for Peripheral Neuropathy (ClinicalTrials.gov) ↗
• Peer-reviewed research on PubMed ↗
• ISSCR patient guide — what to ask ↗
• FDA consumer warning on stem-cell therapies ↗
• EMA — advanced-therapy (ATMP) framework ↗

← Back to Peripheral Neuropathy overview · Peripheral Neuropathy cost →